- Published at
- by manilatimes.net
positive
positive
News for Ultimovacs ASA (ULTIO.OL)
- Published at
- by gurufocus.com
positivepositiveUltimovacs ASA (FRA:7UM) Q4 2024 Earnings Call Highlights: Strategic Merger and Financial Challenges
Cash Position: NOK107 million (approximately $9 million) at the end of Q4 2024.EBIT (Operating Profit): Q4 2024: minus NOK121 million; Full Year 2024: minus NO- Published at
- by gurufocus.com
positivepositiveQ4 2024 Ultimovacs ASA Earnings Call Transcript
Jan 31, 2025 / 08:00AM GMTHans Eid - Ultimovacs ASA - Chief Financial Officer Good morning and welcome to this webcast where we will give a business update and- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
mixedmixed- Published at
- by globenewswire.com
mixedmixedGlobal Stem Cell Market to Cross ~USD 29 Billion Mark by 2030 | DelveInsight
The stem cell market is experiencing positive growth due to several factors, including the increasing prevalence of chronic diseases, the need for drug...- Published at
- by globenewswire.com
mixedmixedGlobal Next-Generation Complement Therapeutics Market to Surge Significantly at a CAGR of ~15% by 2030 | DelveInsight
The next-generation complement therapeutics market is experiencing positive growth driven by the rising global incidence of cardiovascular, genetic,...- Published at
- by globenewswire.com
mixedmixedAdvanced Melanoma Clinical Trial Pipeline Analysis Demonstrates 55+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
Advanced melanoma is when melanoma cells spread from where they started (the primary melanoma) to other parts of the body. The advanced melanoma...- Published at
- by prnewswire.com
mixedmixedCutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and
/PRNewswire/ -- DelveInsight's Cutaneous Melanoma Market Insights report includes a comprehensive understanding of current treatment practices including the...- Published at
- by globenewswire.com
mixedmixedMesothelioma Clinical Trials Pipeline Analysis: 50+ Companies are Working to Improve the Treatment Space | DelveInsight
The prevalence of mesothelioma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence...